BAT Executive Dismisses Focus on Smoking Alternatives

Oct.12.2022
BAT Executive Dismisses Focus on Smoking Alternatives
BAT denies focus on smoking alternatives and plans to maximize growth from portfolio deployment. Transformation continues for a controversial industry.

The top executive of tobacco giant British American Tobacco (BAT) has rebuffed claims that the company will prioritize smoking alternatives, stating that such claims are too superficial.


Kingsley Wheaton, Chief Marketing Officer of British American Tobacco (BAT)


During an interview with City A.M., Chief Marketing Officer Kingsley Wheaton stated that although there may be "more advanced methods" for e-cigarette products in the northern hemisphere, this is driven solely by consumer demand and cigarette pricing.


Whittington stated that the deployment of BAT's investment portfolio, which includes Vuse and Glo, was aimed at achieving "maximum growth." He acknowledged that the tobacco industry remains "controversial" and that there is still a long way to go to achieve transformation. The company, which has a history of 120 years, has been undergoing a transformation plan to shift its customers from cigarette brands like Camel and Rothmans to its alternative products.


Wharton stated that, although growth of the company's new product line in markets such as South Africa, Kenya, and Pakistan has been slow, it is stable. The company is also attempting to identify suitable opportunities in developing markets.


Speaking to City A.M., Whitten said, "We need to provide scalable businesses and appropriate profits. Other regions in developing countries are taking advantage of this opportunity." He explained that some regions, such as Australia and Brazil, cannot achieve this due to strict regulations on tobacco alternatives.


He explained, "When cigarette prices rise, it becomes easier to distance oneself from the tobacco business." He cited the UK's success as an example, where 80% of the price of a pack of cigarettes is made up of taxes.


According to data from Action on Smoking and Health (ASH), the current number of smokers in the UK is five times that of 2012, accounting for approximately 8% of the total population.


Whittington stated that despite the fact that this FTSE 100-listed company's foray into e-cigarettes is still not profitable, it remains committed to its ambitious goal of new category tobacco comprising one-fifth of its overall revenue and profitability by 2025. For a company that serves 175 countries worldwide and generated over £25 billion in revenue in 2021, this goal may seem insignificant.


Statement:


This article is compiled from third-party sources and is intended for industry professionals for the purpose of exchanging and learning information.


This article does not represent the views of 2FIRSTS and 2FIRSTS is not able to confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry communication and research.


Due to limitations in translation expertise, the compiled article may not express the same ideas as the original text. Please refer to the original text for accuracy.


2FIRSTS holds completely aligned positions with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
The U.S. Food and Drug Administration released a programmatic environmental assessment covering nicotine pouches and other oral nicotine products, concluding that their overall environmental impact is generally minimal.
Regulations
May.22
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18
Delaware Tax Proposal Targets Vapes, Nicotine Pouches and Other Tobacco Products
Delaware Tax Proposal Targets Vapes, Nicotine Pouches and Other Tobacco Products
Delaware’s latest tobacco tax increase bill cleared its first House committee hurdle on April 22. Backed by House Speaker Melissa Minor-Brown, the bill would raise the cigarette tax from $2.10 to $3.60 per pack and increase taxes on moist snuff, vapor products and other tobacco products.
Apr.24 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
EU Launches Online Feedback as TPD Revision Enters New Milestone
EU Launches Online Feedback as TPD Revision Enters New Milestone
The European Commission has opened an online call for evidence on revising EU tobacco products and advertising rules, marking a new phase in the TPD/TAD review. Policy options may cover novel products, flavours, packaging, digital marketing and advertising. A 2Firsts review of 855 early submissions shows rapid engagement and recurring debate over differentiated regulation, harm reduction, youth protection, illicit trade and economic impact.
Special Report
May.21
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18